

=> d his

(FILE 'HOME' ENTERED AT 15:33:14 ON 19 MAR 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,  
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,  
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,  
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:33:58 ON  
19 MAR 2003

SEA CD20(10W)B CELL

-----  
47 FILE ADISCTI  
4 FILE ADISINSIGHT  
8 FILE ADISNEWS  
2 FILE BIOCOPMERS  
7 FILE BIOCOMMERCE  
324 FILE BIOSIS  
6 FILE BIOTECHABS  
6 FILE BIOTECHDS  
105 FILE BIOTECHNO  
4 FILE CABA  
215 FILE CANCERLIT  
229 FILE CAPLUS  
5 FILE CEABA-VTB  
26 FILE CIN  
13 FILE CONFSCI  
68 FILE DDFU  
9287 FILE DGENE  
11 FILE DRUGNL  
89 FILE DRUGU  
3 FILE DRUGUPDATES  
7 FILE EMBAL  
238 FILE EMBASE  
126 FILE ESBIOBASE  
12 FILE FEDRIP  
23 FILE GENBANK  
16 FILE IFIPAT  
34 FILE JICST-EPLUS  
52 FILE LIFESCI  
262 FILE MEDLINE  
1 FILE NIOSHTIC  
16 FILE PASCAL  
4 FILE PHAR  
16 FILE PHARMAML  
15 FILE PHIN  
98 FILE PROMT  
250 FILE SCISEARCH  
164 FILE TOXCENTER  
162 FILE USPATFULL  
16 FILE WPIDS  
16 FILE WPINDEX

L1 QUE CD20(10W) B CELL

-----

FILE 'DGENE, BIOSIS, MEDLINE, SCISEARCH, EMBASE, CAPLUS, CANCERLIT,  
TOXCENTER, USPATFULL, ESBIOBASE, BIOTECHNO, PROMT, DRUGU, LIFESCI,  
ADISCTI, JICST-EPLUS, CIN, GENBANK, IFIPAT, PASCAL, PHARMAML, WPIDS,  
PHIN, CONFSCI, FEDRIP, DRUGNL, ADISNEWS, BIOCOMMERCE, ...' ENTERED AT  
15:35:41 ON 19 MAR 2003

L2 11897 S CD20(10W)B CELL  
L3 39 S VACCIN?(10W)CD20

L4 18 DUP REM L3 (21 DUPLICATES REMOVED)  
L5 42 S CD20(25W) (EXTRACELL?) AND DOMAIN  
L6 30 DUP REM L5 (12 DUPLICATES REMOVED)  
L7 5691 S CD20(10W)ANTIBOD?  
L8 17 S L7 AND CD10(10W) (ANTIGEN OR IMMUNOGEN?)  
L9 16 DUP REM L8 (1 DUPLICATE REMOVED)  
L10 372 S B1(20W)CD20 AND (B CELL)  
L11 148 DUP REM L10 (224 DUPLICATES REMOVED)  
L12 166 S L10 AND B1(25W)ANTIBOD?  
L13 75 DUP REM L12 (91 DUPLICATES REMOVED)  
L14 425 S B1(25W)VACCINE  
L15 250 DUP REM L14 (175 DUPLICATES REMOVED)  
L16 19 S L14 AND (CANCER OR TUMOR OR TUMOUR)  
L17 15 DUP REM L16 (4 DUPLICATES REMOVED)

=>

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS  
AN 1997:8270 CAPLUS  
DN 126:103042  
TI Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide  
AU Hooijberg, Erik; Visseren, Marjan J. W.; Van Den Berk, Paul C. M.; Jellema, Anke P.; Romeijn, Petra; Sein, Johan J.; Van Der Voort, Ellen I. H.; Hekman, Annemarie; Ossendorp, Ferry; Melief, Cornelis J. M.  
CS Department of Immunology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, Neth.  
SO Journal of Immunotherapy with Emphasis on Tumor Immunology (1996), 19(5), 346-356  
CODEN: JIEIEZ; ISSN: 1067-5582  
PB Lippincott-Raven  
DT Journal  
LA English  
AB Cytotoxic T lymphocytes (CTL) play an important role in the destruction of immunogenic tumors. A novel category of target antigens for CTL concerns normal differentiation antigens as most clearly demonstrated in human melanoma. In the case of B-cell cancers, differentiation antigens normally expressed on B cells may be useful targets. In this report, we have focused on the murine B-cell differentiation antigens CD19 and CD20. We have identified 18 peptide sequences on the basis of major histocompatibility complex (MHC) class-I binding-motifs as candidates for the induction of autoreactive CTL. Six of the peptides were capable of binding efficiently to either Kb or Db and were subsequently used for in vivo induction of CTL. Vaccination with each of three peptides led to peptide-specific CTL. Two peptides were derived from the mCD20 antigen and one from the mCD19 antigen. CTL specific for the mCD19-derived peptide were also capable of killing a syngeneic B-cell tumor line. Recognition of the peptide as well as the tumor cells was shown to be Kb restricted. This is the first report to show that autoreactive CTL recognizing peptides derived from B-cell-specific differentiation antigens can be generated by vaccination with a synthetic peptide.  
IT Lymphoma  
(B-cell; vaccination with CD19 or CD20 peptides induces cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in mice)  
IT 185856-50-2 185856-51-3  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(vaccination with CD19 or CD20 peptides induces cytotoxic T-lymphocytes that lyse syngeneic B-cell tumors in mice)

*Please write on this page*